{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-030466","form_type":"8-K","ticker":"ADTX","cik":"0001726711","company_name":"Aditxt, Inc.","filed_at":"2024-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.763621+00:00","generated_at":"2026-06-04T02:22:06.648609+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aditxt signs agreement to acquire Appili Therapeutics for $5.7M cash plus stock","bullets":["Acquisition for ~$5.7M cash plus ~332,876 Aditxt shares; ~$0.0467/sh + 0.002745 ADTX share per Appili share.","Assets include FDA-approved LIKMEZ, DoD-funded ATI-1701 tularemia vaccine ($14M award), and ATI-1801 topical leishmaniasis treatment.","Closing conditioned on Aditxt raising at least $20M financing by June 30, 2024; termination fee of CDN$1.25M if not met.","Transaction requires Appili shareholder vote, court approval, and NASDAQ listing of Consideration Shares.","Outstanding Appili options/warrants cashed out for additional ~$341,000 aggregate."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-030466","json":"https://secwatch.observer/filing/0001213900-24-030466.json","markdown":"https://secwatch.observer/filing/0001213900-24-030466.md","text":"https://secwatch.observer/filing/0001213900-24-030466.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390024030466/0001213900-24-030466-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390024030466/ea0203328-8k_aditxtinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:22:06.648609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7450f7fe76353ee5df91527fe0fadea316465ef7","claim":"Aditxt, Inc. entered into Arrangement Agreement with Appili Therapeutics, Inc. (effective 2024-04-01).","evidence_excerpt":"On April 1, 2024 (the “ Execution Date ”), Aditxt, Inc., a Delaware corporation (the “ Company ”), entered into an Arrangement Agreement (the “ Arrangement Agreement ”) with Adivir, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Adivir ” or the “ Buyer ”), and Appili Therapeutics, Inc., a Canadian corporation (“ Appili ”), pursuant to which, Adivir will acquire all of the issued and outstanding Class A common shares of Appili","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1726711/000121390024030466/0001213900-24-030466-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Appili Therapeutics, Inc."},{"label":"Effective","value":"2024-04-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}